Key result
Diverse preclinical models from animals to organoids enable testing and validation of AF therapies.
Why the study?
Testing and validating therapeutic interventions for atrial fibrillation requires carefully choosing an appropriate preclinical model to refine and optimise therapy.
This review provides a comprehensive overview of preclinical models for atrial fibrillation, aiding researchers in selecting appropriate models for therapeutic testing.
No takes yet. Share an insight, caveat, or question.
Aids AF model selection for therapeutic testing; leaves open which platforms best predict clinical efficacy.
Baena-Montes et al. (2023) conducted a review in Atrial Fibrillation. Preclinical models (in vitro, animal, organoids, organs-on-a-chip) was evaluated. A broad range of preclinical models, from traditional animal models to state-of-the-art organoids and organs-on-a-chip, are available to test and validate therapeutic interventions for atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: